Cellular phase chronic idiopathic myelofibrosis
disease diseaseOn this page
Also known as chronic idiopathic myelofibrosis, cellular phasechronic idiopathic myelofibrosis, Prefibrotic stagePMFPESPrefibrotic/Early Primary myelofibrosisprimary myelofibrosis, Prefibrotic stageprimary myelofibrosis, Prefibrotic/early stage
Summary
Cellular phase chronic idiopathic myelofibrosis (MONDO:0004463) is a disease and 10 clinical trials. Top therapeutic interventions include aspirin, ropeginterferon alfa-2b, and ruxolitinib. A subtype of primary myelofibrosis — broader associated-gene and molecular evidence is on the parent page (see Disease family below).
At a glance
- Clinical trials: 10
Clinical features
No curated clinical features (Orphanet) for this disease.
Identifiers
Disease identifiers
| Field | Value |
|---|---|
| Canonical name | cellular phase chronic idiopathic myelofibrosis |
| Mondo ID | MONDO:0004463 |
| DOID | DOID:8106 |
| NCIT | C41237 |
| UMLS | C1516553 |
| MedGen | 275741 |
| GARD | 0024019 |
| Is cancer (heuristic) | no |
Also known as: chronic idiopathic myelofibrosis, cellular phase · chronic idiopathic myelofibrosis, Prefibrotic stage · PMFPES · Prefibrotic/Early Primary myelofibrosis · primary myelofibrosis, Prefibrotic stage · primary myelofibrosis, Prefibrotic/early stage
Disease family
This is a subtype of primary myelofibrosis. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.
Classification path: disease › human disease › disease by body system or component › hematologic disorder › anemia › aplastic anemia › acquired aplastic anemia › primary myelofibrosis › cellular phase chronic idiopathic myelofibrosis
Related subtypes (3): familial myelofibrosis, panostotic fibrous dysplasia, myelofibrosis with myeloid metaplasia
Genetics & variants
GWAS landscape
No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.
Variant details and genetic-evidence tiers
No tiered GWAS variants or ClinVar records for this disease.
Genes & proteins
No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).
Function
No pathway enrichment — requires an associated-gene cohort.
Therapeutics
No druggable-target or therapeutic data for this disease’s cohort.
Clinical trials & evidence
Clinical trials
Clinical trials: 10.
Phase distribution (across all retrieved trials)
| Phase | Trials |
|---|---|
| Not specified | 6 |
| PHASE3 | 1 |
| PHASE1/PHASE2 | 1 |
| PHASE2 | 1 |
| PHASE1 | 1 |
Top trials by phase / activity
| NCT | Phase | Status | Title |
|---|---|---|---|
| NCT05198960 | PHASE3 | RECRUITING | AVAJAK: Apixaban/Rivaroxaban Versus Aspirin for Primary Prevention of Thrombo-embolic Complications in JAK2V617F-positive Myeloproliferative Neoplasms |
| NCT03862157 | PHASE1/PHASE2 | ACTIVE_NOT_RECRUITING | Azacitidine, Venetoclax, and Pevonedistat in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia |
| NCT04988815 | PHASE2 | UNKNOWN | Ropeginterferon Alfa 2b for Early Myelofibrosis |
| NCT02528877 | PHASE1 | WITHDRAWN | Ruxolitinib Phosphate, Tacrolimus and Sirolimus in Preventing Acute Graft-versus-Host Disease During Reduced Intensity Donor Hematopoietic Cell Transplant in Patients With Myelofibrosis |
| NCT04942080 | Not specified | RECRUITING | Interest of CALR Allele Burden in Diagnosis and Follow-up of Patients With CALR Mutated Myeloproliferative Syndromes (CALRSUIVI) |
| NCT05882773 | Not specified | RECRUITING | Asian Myeloproliferative Neoplasm (MPN) Registry |
| NCT03116542 | Not specified | UNKNOWN | 18F-FLT (PET/CT) in Prefibrotic/Early Primary Myelofibrosis and Essential Thrombocythemia |
| NCT03121599 | Not specified | TERMINATED | 18F-FLT (PET/CT) in Pediatrics With Myeloproliferative Neoplasms |
| NCT03869476 | Not specified | COMPLETED | Pilot Study for the Development of a Diagnostic Score to Differentiate Myeloproliferative Neoplasms. |
| NCT06371573 | Not specified | COMPLETED | Ultrasound Examination for Spleen Volume Evaluation in Myeloproliferative Neoplasms |
Drugs tested across these trials (top 30)
| Molecule | Max phase | Trials referencing |
|---|---|---|
| ASPIRIN | 4 | 1 |
| ROPEGINTERFERON ALFA-2B | 4 | 1 |
| RUXOLITINIB | 4 | 1 |
| PEVONEDISTAT | 3 | 1 |